The Exchange has sought clarification from Fischer Medical Ventures Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted. The response of the Company is awaited.
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Fischer Medical Ventures Limited to provide clarification on its December 2025 quarter results under SEBI's Listing Obligations and Disclosure Requirements (Regulation 33). The specific gap flagged is that segment-wise details were not submitted along with the financial results. The company has not yet responded, and its reply is awaited. Regulation 33 governs the submission of quarterly financial results to stock exchanges, and missing segment reporting is a common procedural compliance query. No penalty or action has been announced — this is currently a request for information.
This is a routine procedural clarification and not a punitive action, so near-term impact on shareholders is likely limited. However, investors should watch for the company's response, as repeated non-compliance with disclosure norms could attract penalties or affect trading sentiment.